Compugen醫療 CGEN 深 滬
等待開盤 10-28 09:30:00 美东时间
1.97
+0.095
+5.07%
華盛通- 最 高1.97
- 今 開1.92
- 成交量 13.14万股
- 最 低 1.88
- 昨 收 1.875
- 總市值 1.87亿
- 52周最高 3.235
- 市盈率 靜 5.23
- 換手率 0.14%
- 52周最低 1.43
- 委 比 46.77%
- 總股本 9472.79万
- 歷史最高 19.90
- 量 比 0.35
- 振 幅 4.80%
- 歷史最低 0.51
- 每 手 1
- 風險率 0.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Compugen医疗收涨5.07%，成交额25.48万美元
10月28日，Compugen医疗（CGEN）收涨5.07%，报1.97美元，成交额25.48万美元，市值1.87亿美元。 行情数据 • 开盘价：1.92美元...
今天 06:43
Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026
HOLON, Israel, Oct. 26, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery pow...
10-26 19:00
Compugen医疗收涨0.51%，成交额31.44万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-20 06:46
Compugen医疗收跌5.77%，成交额33.7万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:46
美股大行评级 | 潜在涨幅386.16%！摩根士丹利维持TeraWulf"超配"评级，上调目标价至65美元
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从62.5美元升至65美元；摩根士丹利：维持Hut 8"超配"评级，目标价从273美元升至275美元
10-13 12:30
HC Wainwright & Co. Reiterates Buy on Compugen, Maintains $4 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Compugen (NASDAQ:CGEN) with a Buy and maintains $4 price target.
10-12 19:30
Compugen Q2 EPS $(0.07), Inline, Sales $2.602M Beat $1.606M Estimate
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 12.5 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $2.602 million which beat the analyst consensus est...
08-03 19:01
Compugen Reports Second Quarter 2026 Results
COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the interim analysis expected by Q1 2027 Trial-in-progress poster on MAIA-ovarian presented a...
08-03 19:00
Compugen To Present Trial-In-Progress Poster On MAIA-Ovarian Phase 1 Study Of COM701, Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026
Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701, a potential first-in-c...
06-11 19:14
Compugen Q1 2026 Earnings Call: Complete Transcript
On Monday, Compugen (NASDAQ:CGEN) discussed first-quarter financial results dur...
06-01 21:04
